X4 Pharmaceuticals Inc. (XFOR) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, X4 Pharmaceuticals Inc. (NASDAQ: XFOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $3.36 (+0.30% 1D, market cap $333.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, XFOR ranks #817 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), XFOR carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 83.6%, and ROIC of -35.0%. By comparison, ALEC (Alector Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $332.1M) and SCTX (Scribe Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC —, cap $330.2M). Among the 5-stock peer group, XFOR leads on earnings multiple (N/A) while XFOR leads on capital efficiency (-35.0% ROIC).
Per XFOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501697), X4 Pharmaceuticals Inc. generated $35.1M in revenue (+1273.2% YoY), -$79.2M in net income, and -$85.6M in free cash flow against $290.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 39% of 52W Range • RSI-14 at 60.3 (BULLISH MOMENTUM)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While XFOR currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.33) and Max Pain ($3.53) forces dealer call-delta covering toward $5.07.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
X4 Pharmaceuticals Inc. (XFOR) advanced +0.30% to $3.36, trading at 39% of its 52-week range ($2.43 – $4.83). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day October 29, 2026 10:00 AM EDTCompany ParticipantsAdam Craig - Executive ChairJohn Volpone - President...
- Base Case U.S. Market Opportunity Estimated at 15,000 Patients, With Potential to Expand to Approximately 30,000 Patients - - On Track for Completion of 4WARD Phase 3 Target Enrollment in Q4 2026 - - Planned 4STEPS Pha
X4 Pharmaceuticals (NASDAQ:XFOR) said it expects to complete enrollment in its pivotal Phase III 4WARD trial of mavorixafor for primary chronic neutropenia, or PCN, by the end of the fourth quarter of 2026, with top-line
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XFOR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XFOR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, X4 Pharmaceuticals Inc. (XFOR) ranks #817 by composite RQD confidence (35/100, grade D-) and #507 by equity capitalization ($333.1M). Within this direct 5-issuer industry benchmark cohort, XFOR leads on earnings valuation at N/A trailing P/E, while XFOR leads on capital efficiency and profitability with -35.0% ROIC and 83.6% gross margin. SCTX currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with XFOR at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XFOR
ACTIVE
X4 Pharmaceuticals Inc. | D- | 35/100 | — | 83.6% | -35.0% | +0.30% | $333.1M | Benchmark Subject |
| ALEC Alector Inc. | E | 32/100 | — | — | -35.0% | -0.44% | $332.1M | /alec-vs-xfor → |
| SCTX Scribe Therapeutics Inc. | D | 50/100 | — | — | — | -0.57% | $330.2M | /sctx-vs-xfor → |
| IRLA IRulya Therapeutics Inc. | E | 32/100 | — | — | -35.0% | -4.05% | $342.8M | /irla-vs-xfor → |
| AGEN Agenus Inc. | E | 26/100 | — | 96.0% | -35.0% | -0.56% | $320.2M | /agen-vs-xfor → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), X4 Pharmaceuticals Inc. (XFOR) reported GAAP revenue of $35.1M (+1273.2% vs. FY2024 revenue of $2.6M ) , GAAP net income of -$79.2M, operating cash flow of -$85.6M, and free cash flow of -$85.6M (+34.8% YoY). On the balance sheet, XFOR closed FY2025 with $290.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $35.1M | -$79.2M | -$85.6M | -$85.6M | $290.5M | — |
| FY2024 (FY) | 2024-12-31 | $2.6M | -$37.5M | -$130.9M | -$131.2M | $146.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$101.2M | -$96.5M | -$96.5M | — | — |
As of 2026-11-01, X4 Pharmaceuticals Inc. (NASDAQ: XFOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $3.36 (+0.30% 1D, market cap $333.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, XFOR ranks #817 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), XFOR carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 83.6%, and ROIC of -35.0%. By comparison, ALEC (Alector Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $332.1M) and SCTX (Scribe Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC —, cap $330.2M). Among the 5-stock peer group, XFOR leads on earnings multiple (N/A) while XFOR leads on capital efficiency (-35.0% ROIC).
Per XFOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501697), X4 Pharmaceuticals Inc. generated $35.1M in revenue (+1273.2% YoY), -$79.2M in net income, and -$85.6M in free cash flow against $290.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
XFOR last traded at $3.36 (+0.30% on volume of 911,233 shares), positioning the stock +0.90% above its 50-day simple moving average ($3.33) and -11.58% below its 200-day simple moving average ($3.80). Across its 52-week range of $2.43 to $4.83, XFOR sits at the 38.7% percentile with a 14-day RSI of 60.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.94 to $3.78).
Why XFOR Stock advanced +0.30% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.